The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The following is a summary of “Reducing time delays and enhancing reperfusion eligibility related to stroke suspicion by the ...

Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

On February 27, 2025, the Emergency Department team at Mercer Health was recognized by the Ohio State University Wexner ...

New research shows that stress may increase the risk of stroke in younger women. Experts explain the stress-stroke connection ...

For patients with acute ischemic stroke whose symptoms began 4.5 to 24 hours earlier, alteplase is associated with a higher percentage of patients achieving a score of 0 or 1 on the modified Rankin ...

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...

A new study found that moderate stress levels were associated with a 78% increased risk of stroke in female participants, but ...

A study has uncovered that iron orchestrates the activation of two damaging cell death pathways—ferroptosis and ...

Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or ...